U.S. Markets close in 5 hrs 14 mins

Astellas Pharma Inc. (ALPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
13.010.00 (0.00%)
As of 10:16AM EDT. Market open.
People also watch
Full screen
Previous Close13.01
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume793
Market Cap26.08B
PE Ratio (TTM)15.34
Earnings DateN/A
Dividend & Yield0.30 (2.34%)
Ex-Dividend Date2017-03-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 days ago

    UAB makes headway with new osteoporosis drug

    A new drug that boosts bone formation has been shown to reduce the risk of bone fractures in women with osteoporosis, according to a study from UAB's department of medicine. “There have been limited studies comparing drugs that help build bone against drugs that work by slowing bone loss,” said Kenneth Saag, professor in the Division of Clinical Immunology and Rheumatology, in the UAB Department of Medicine, and first author of the study.

  • Why Did Pfizer (PFE) Stock Pop Today?
    Zacks11 days ago

    Why Did Pfizer (PFE) Stock Pop Today?

    Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.

  • Reuters11 days ago

    Pfizer, Astellas prostate cancer drug promising in late-stage trial

    Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body.